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Background
CD4 gains under antiretroviral treatment might come
from cells recently migrated from the thymus or from
cells proliferating in the periphery. CD31 on the surface
of CD4+ T cells has been shown to identify recent thy-
mic emigrants. We evaluated the characteristics of the
CD4 gain observed in patients switching to a Raltegravir
(RAL) containing regimen.
Methods
Patients on highly active antiretroviral therapy (HAART)
with long-term suppressed viremia were selected and
divided according to treatment: switched to RAL vs.
maintained the same regimen (control group). Samples
were collected at the time of RAL switch (0) and six
months after (+6). Immune parameters were assessed in
peripheral blood mononuclear cells (PBMCs) using five-
colour flow cytometry. Analysis of naïve and memory
CD4+ Tcells (CD45RA and CD27) was combined with
measurements of activation (CD38) and with CD31
expression. Results were reported as median [IQR] and
comparisons were performed with Mann-Whitney tests.
Results
Thirty-seven patients (19 RAL and 18 control) were
selected. Baseline characteristics did not differ among
groups for CD4+ T cell count (322 cells/mm
3 [204-
499]) and percentage (18% [12.5-26.5]), age (44 years
old [41.5-48]) and time with suppressed viremia (2.12
years [0.84-4.80]).
Six months after switching to RAL, CD4+ T cell count
was significantly higher than baseline (448 [288-575] vs.
322 [242-594] cells/mm
3, p=0.026), while patients who
did not switch to RAL maintained stable CD4 values
(330 [176-425] vs. 312 [141-478], p=0.813).
No differences were observed from 0 to +6 in any
group for immune activation or CD31 expression. How-
ever, in the RAL group, the proportion of naïve CD4+ T
cells increased six months after the switch (from 18.2%
[9.3-29.3] to 23.7% [12.7-31.4], p=0.014), while the level
of effector memory CD4+ T cells experienced a signifi-
cant decrease (13.3% [9-21.3] vs. 10.2% [5.5-16.8],
p=0.005). All these subsets remained stable in the con-
trol group during the follow up.
Conclusions
Switching to a RAL-containing regimen induced a sig-
nificant gain in CD4+ T cell count compared with
patients who maintained the same treatment. This
improvement was mainly due to an increase in CD4
naïve cells. However, it could not be explained by an
increase of the thymic function, suggesting that CD4
gains under RAL treatment may come from peripheral
expansion.
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